Plant Impact plc today announced that it has signed an agreement with Bayer CropScience to develop yield enhancing technologies for soy cultivation. The agreement encompasses a multi-year partnership for Plant
Sigma-Aldrich (NASDAQ – SIAL) Reports Record Full-Year 2014 Sales Of $2.79 Billion And Record Adjusted Diluted EPS Of $4.37. Reports Q4 2014 Adjusted Diluted EPS Of $1.14 And Organic Sales
Pharma giants Merck, Sanofi & GSK announced their full-year results for 2014 this week, as did global AgroChemical multinational Syngenta. Syngenta reported sales of $15.1 billion USD, achieving their integrates
Thermo Fisher Scientific have announced their acquisition of ASI (Advanced Scientifics, Inc.) for a cash payment of $300 million USD as the company seeks to strengthen their bioproduction offerings. ASI
Up until now uncultured bacteria have been an untapped source of new antibiotics, but promising research published in Nature yesterday highlights novel in-situ methods for growing uncultured microorganisms. One of
Academic publishing giant Elsevier have announced the forthcoming launch of a new open access multi-disciplinary scientific journal, calling for researchers to adopt a new collaborative and open source ethos. Dr.
Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech
BioReliance® Introduces Advanced In Vitro ADME and Toxicology Services Designed to Improve Drug Safety and Efficacy BioReliance® (www.bioreliance.com), Sigma-Aldrich Corporation’s (NASDAQ: SIAL) biologics and early-development services business under SAFC® Commercial
Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry Merck to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion)
Lonza Half-Year Business Performance Fully on Track Business is fully on track with a CORE EBIT growth of 13.1% compared with the first half of 2013 despite currency headwinds Revenue
Roche delivers solid sales growth for the first nine months of 2014 Group sales up 5% at CER1, stable in Swiss francs 4% higher sales in Pharmaceuticals Division, with strong
Sigma-Aldrich (NASDAQ – SIAL) Reports Q3 2014 Results With Sales Of $690 Million And Adjusted Diluted EPS Of $1.06. Declares $0.23 Per Share Quarterly Dividend. Q3 2014 Results (all percentage
Pacific Biosciences reported a 178% increase in revenue to $20.6 million for the third quarter ended September 30, 2014, compared to $7.4 million for the third quarter of 2013. Third
